Forskolin versus sodium cromoglycate for prevention of asthma attacks: a single-blinded clinical trial

J Int Med Res. Mar-Apr 2006;34(2):200-7. doi: 10.1177/147323000603400210.

Abstract

To determine the efficacy of forskolin in preventing asthma attacks, we performed a single-blinded clinical study in children and adult out-patients at a public hospital in Mexico. Forty patients of either sex with mild persistent or moderate persistent asthma were assigned randomly to 6 months of treatment with forskolin at 10 mg/day orally (capsules) or with two inhalations of sodium cromoglycate every 8 h, i.e. three times a day. The number of patients who had asthma attacks during the treatment period was significantly lower among those receiving forskolin (8/20, 40%) than among those receiving sodium cromoglycate (17/20, 85%). Values of forced expiratory volume in 1 s and forced expiratory flow, mid-phase, A similar in the two groups during the treatment period. We conclude that forskolin is more effective than sod cromoglycate in preventing asthma attacks in patients with mild persistent or moderate persistent asthma.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Asthma / prevention & control*
  • Child
  • Colforsin / therapeutic use*
  • Cromolyn Sodium / therapeutic use*
  • Female
  • Forced Expiratory Volume / drug effects
  • Humans
  • Male
  • Maximal Midexpiratory Flow Rate / drug effects
  • Middle Aged
  • Single-Blind Method

Substances

  • Anti-Asthmatic Agents
  • Colforsin
  • Cromolyn Sodium